US 12,383,567 B2
Use of cannabinoids in the treatment of epilepsy
Geoffrey Guy, Cambridge (GB); and Volker Knappertz, Cambridge (GB)
Assigned to Jazz Pharmaceuticals Research UK Limited, Sittingbourne (GB)
Appl. No. 16/768,241
Filed by Jazz Pharmaceuticals Research UK Limited, Sittingbourne (GB)
PCT Filed Nov. 30, 2018, PCT No. PCT/GB2018/053483
§ 371(c)(1), (2) Date May 29, 2020,
PCT Pub. No. WO2019/106386, PCT Pub. Date Jun. 6, 2019.
Claims priority of application No. 1720020 (GB), filed on Dec. 1, 2017.
Prior Publication US 2021/0177773 A1, Jun. 17, 2021
Int. Cl. A61K 31/05 (2006.01); A61K 31/00 (2006.01); A61K 36/185 (2006.01); A61P 25/10 (2006.01); A61P 25/12 (2006.01); A61K 31/436 (2006.01)
CPC A61K 31/658 (2023.05) [A61K 36/185 (2013.01); A61P 25/10 (2018.01); A61P 25/12 (2018.01); A61K 31/436 (2013.01)] 12 Claims
 
1. A method of treating childhood-onset epilepsy in a patient who is concurrently taking tacrolimus, comprising:
administering to the patient a drug substance comprising at least 98% (w/w) cannabidiol (CBD) and less than 0.15% (w/w) THC;
detecting toxic blood levels of tacrolimus or one or more associated markers; and
reducing the dose of tacrolimus to no more than 5 mg per day.